Rilzabrutinib

Rilzabrutinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Graves' Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Rilzabrutinib 研究

• A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

  II 期招募中Argentina加拿大Chile德国NCT06984627

• The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

  III 期招募中美国比利时Brazil法国NCT06975865

• Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  III 期招募中美国奥地利Czechia法国NCT07007962

• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

  II 期招募中美国Argentina澳大利亚BrazilNCT06500702

• A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

  III 期招募中美国Argentina奥地利BrazilNCT07086976

• A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

  III 期招募中美国Argentina比利时加拿大NCT07190196

• Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function

  I 期招募中美国NCT07853131

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。